Roka Bioscience receives AOAC Certification for the Atlas Listeria Environmental Detection Assay

New assay co-developed with the industry, specifically designed to meet the unique challenges of Listeria Environmental testing

Jul 14, 2015

WARREN, N.J., July 14, 2015 /PRNewswire/ -- Roka Bioscience, Inc. (NASDAQ: ROKA) announced today that its Atlas Listeria Environmental Detection Assay (Atlas LE Assay) has received AOAC Performance Tested MethodsSM certification from the AOAC Research Institute (AOAC-RI). The assay is approved for the detection of Listeria spp. (including Listeria monocytogenes, Listeria innocua, Listeria welshimeri, Listeria ivanovii, Listeria seeligeri, and Listeria grayi) from environmental surfaces (stainless steel grade 316, plastic (PVC), and sealed concrete) after a 24 hour enrichment. The independent laboratory study testing was conducted by Marshfield Food Safety LLC, as part of the AOAC-RI independent third-party evaluation and validation processes. "With recent events involving Listeria outbreaks we believe that environmental testing plays an important role for food safety," stated Mary Duseau, Chief Commercial Officer at Roka Bioscience.

Roka Bioscience

About Roka Bioscience

Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our "sample-in, result-out" Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.  For more information, visit http://rokabio.com.

About AOAC-RI

The AOAC Research Institute (AOAC-RI) is a wholly owned subsidiary of AOAC INTERNATIONAL (AOAC) that administers AOAC's conformity assessment, including the AOAC Performance Tested MethodsSM program. AOAC is a globally recognized, independent, not-for-profit standards developing association founded in 1884. AOAC serves the analytical community by engaging industry stakeholders to develop voluntary consensus standards for methods and providing analytical methods that demonstrate confidence in analytical results. For more information on the AOAC-RI and AOAC, visit the AOAC website at www.aoac.org.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended (the "Exchange Act"). These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. Any statements contained herein (including, without limitation, statements to the effect that we "believe", "expect", "anticipate", "plan" and similar expressions) that are not statements of historical fact should be considered forward-looking statements. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include those set forth in the company's filings with the Securities and Exchange Commission. We expressly disclaim any obligation to update any forward-looking statements, except as may be required by law.  Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this press release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

For Investor or Media Related Inquires Please Contact:
Roka Bioscience, Inc.
ir@rokabio.com
855-ROKABIO (855-765-2246)

Logo - http://photos.prnewswire.com/prnh/20150714/236470LOGO

SOURCE Roka Bioscience


print email rss